Xavo, a leading provider of Software-as-a-Service for Biopharma R&D is pleased to announce that Accent Therapeutics has gone live with the latest version of Xavo R3. - “We are very happy to continue the successful partnership with Accent and to have them as a customer of our cloud-based Sample Management SaaS”, says Reda Bensaid, Xavo’s CEO.
Accent Therapeutics, Inc., a Lexington, MA based biopharmaceutical company who is focusing on the RNA modification space to deliver the next generation of cancer therapies, has been a user of Xavo’s cloud-based Sample Management system since 2019. With growing needs in managing their inventory of small molecule samples across several CROs and to make samples of compounds better available for their scientists, Accent turned to Xavo in 2022 to upgrade to the latest version of the product, which is Xavo R3.
Following Xavo’s standard process and out-of-the-box product functionality, the joint team was able to configure the platform to enable Accent’s agile and distributed scientific operations. “At Accent, we are focused on translating extraordinary science to life-changing therapies for patients in need.”, says Gina Prophete, Manager, Sample Management at Accent. She continues: “Efficiencies and accuracy in our workflows are critical to ensuring our scientists’ work in support of our mission is well-supported. The Xavo system is an important component of our daily workflow in providing samples to our scientists. The upgrade to Xavo R3 has helped us to reduce the manual effort in executing sample orders and feel more confident in the speed and precision of our workflow. “
Rami Lokas, Xavo’s VP Value Realization says: “Xavo is proud to have been a partner with Accent for several years. The recent upgrade to Xavo R3 highlights our commitment to continually providing better Sample Management solutions to our customers and the marketplace. Xavo’s state-of-the-art cloud-based SaaS solution for Sample Management helps Accent manage sample inventories across several CROs. We look forward to continually delivering on expanded functionality through our subscription model at no additional cost to our customers.”